Navigation Links
Founder of Curidium Launches Elixior, an Advisory Company Focused on the Development and Growth of Innovative Personalized Medicine Businesses
Date:9/6/2009

LONDON, September 7 /PRNewswire/ -- Elixior Limited, the advisory company focused on the development and growth of innovative personalized medicine businesses, announced today its launch by the founder and former CEO of Curidium, Dr Anne Bruinvels.

    Elixior's business activities are aimed at:

    - Supporting the development and growth of personalized medicine
      businesses through the creation of partnerships and / or the sourcing
      of investments

    - Helping personalized medicine companies with the structuring of their
      corporate and commercial strategies

    - Conducting due diligence on personalized medicine ventures

    - Building a world-wide, personalized medicine knowledge-base to support
    cooperation between personalized medicine businesses and the growth of
    the sector.

Dr Anne Bruinvels, founder and CEO of Elixior, commented: "The field of personalized medicine is moving forward rapidly and it is Elixior's aim to help the development and commercialization of new innovations in this exciting area. Personalized medicine has the potential to treat patients more effectively and to make healthcare much more cost-effective over time. I look forward to working with small and big companies alike planning to move into or expand in this field."

Previously, Dr Anne Bruinvels founded Curidium, a personalized medicine company focused on improving the diagnosis and treatment of central nervous system disorders. She was Curidium's CEO for more than six years, during which she took the company public on the AIM of the London Stock Exchange.

About Personalized Medicine

The term personalized medicine means the use of molecular analysis methods to better manage a patient's disease or disease predisposition. These methods include testing for variations in genes, gene expression, proteins, and metabolites. Test results are correlated wi
'/>"/>

SOURCE Elixior Limited
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine news :

1. Kenneth G. Langone, Home Depot Co-Founder, Chairman of the NYU Langone Medical Center, to Lead 65th Annual Columbus Day Parade as Grand Marshal
2. Laurence Barsh, DMD, Founder of Snoring Isn't Sexy, LLC Emphasizes Need to Evaluate and Treat Sleep Patients
3. AMERIGROUP Foundation Honors Warehouse of Hope Founder Craig Parson as a Healthy Hero
4. Laurence I. Barsh, DMD, Founder of Snoring Isn't Sexy, to speak at Somnomed's First Annual Symposium
5. Randall Terry, Founder, Operation Rescue: Abortion, Healthcare, and Social Upheaval: Pro-life Leaders to Discuss Backlash -- Including Potential of Unwanted Violence
6. Miles To End Malaria Program Gets an Extra Burst of Speed From American Le Mans Series Founder Don Panoz
7. Founders of Running Skirts Inc. Set to Launch New Maternity Line
8. Founder and CEO of HealthTech, Molly Coye, MD, Assumes Leadership of CalRHIO
9. Angelo Masciantonio, CEO and Co-Founder of HTH Worldwide Named Ernst & Young 2009 Entrepreneur Of The Year(R) in Greater Philadelphia
10. Chopra Center Co-Founder and Best-Selling Author David Simon, M.D., Will Lead Two Special Events in New York City This June
11. Medeguide Founder to Lead Online Healthcare Marketing Workshop at the Healthcare Travel Conference in Singapore

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...sContinuetoTargetIndividualsintheRecommendedPriori...USNewswire/--TheDepartmentofHealthannouncedtodayth...atlocalStateHealthCentersinDelaware,Lancaster,andL...TheH1N1vaccinewillbeadministeredforfreetoindividua...usaccesstothevaccine.Thedepartmentasksthatonlyindi...
(Date:11/23/2009)...rs of cancer patients and survivors treated with c...t often become chronic conditions, hindering patie...ists at the University of Rochester Medical Center...xperienced sleep troubles at nearly three times th...more prevalent in younger patients and those with ...
(Date:11/23/2009)...v. 23, 2009) -- A first-of-its-kind consensus stat...y in the Annals of Surgery . The report illustrat...us conference -- Diabetes Surgery Summit (DSS) -- ...tific and medical experts agreed on a set of evide...t to guide the use and study of gastrointestinal s...
(Date:11/23/2009)...oubled number of patients who reined in their hype... 23 (HealthDay News) -- High blood pressure is bet...hand-in-hand than by doctors and pharmacists worki... work with pharmacists, medications are intensifie...ively," said Barry L. Carter, a professor in the U...
(Date:11/23/2009)...ershipswithMinorityBanksin Washington D.C. , .... IntendedtoSpurEconomicGrowthandRevitalization ...--DaVita,thenation,sleadingproviderofdialysisservi...acostiacommunityfora$1millioninvestmentinIndustria...ycommunities. ,, DaVita,sinvestmentinWashington...
Breaking Medicine News(10 mins):Health News:Pennsylvania Department of Health Announces Additional H1N1 Vaccination Clinics in Delaware, Lancaster, Lehigh Counties 2Health News:Insomnia prevalent among cancer patients who receive chemotherapy 2Health News:Diabetes surgery summit consensus lays foundation for new field of medicine 2Health News:Diabetes surgery summit consensus lays foundation for new field of medicine 3Health News:Diabetes surgery summit consensus lays foundation for new field of medicine 4Health News:Diabetes surgery summit consensus lays foundation for new field of medicine 5Health News:Doctor-Pharmacist Teams Boost Blood Pressure Control 2Health News:Doctor-Pharmacist Teams Boost Blood Pressure Control 3Health News:DaVita Launches Minority Bank Initiative with $1 Million Investment in Industrial Bank of Washington, D.C. to Support Underserved Communities 2Health News:DaVita Launches Minority Bank Initiative with $1 Million Investment in Industrial Bank of Washington, D.C. to Support Underserved Communities 3Health News:DaVita Launches Minority Bank Initiative with $1 Million Investment in Industrial Bank of Washington, D.C. to Support Underserved Communities 4
...er cells form by hijacking a developmental genetic...Scientists at the Georgia Institute of Technology ...he protein, PAX8, is involved in the development o...c and therapeutic interventions, but also opens ne...
...cereal-eating physicians taking part in the Physic...ngs// of wholegrain breakfast cereals reduced thei...research, presented last week at the American Hear...onsumption of wholegrain products to improvements ...
...er mental health conditions are potentially around...of Iowa study. The findings, which were based ...te blood cells, appear online March 6 in the Ameri...hilibert, M.D., Ph.D., professor of psychiatry in ...
...iversity of Leicester geologist was recently used ...m// Oversight Board to detect exposure of UK troop...nflict. Randall Parrish, Professor of Iso...t Horstwood at the British Geological Survey, usin...
...d that it may be possible to detect certain mental...tests//. This was revealed after scientists studie...cells. "The ability to test for panic disorde...A. Carver College of Medicine. "Panic disord...
...e under ongoing stress have more fevers with illne...t children’s natural killer cell function, part of...chronic stress, unlike adults, whose function is d...lth," said Mary Caserta, M.D., principal investiga...
Other Medicine News:Health News:Ovarian Cancer May Mimic Fallopian Tube Formation 2Health News:Ovarian Cancer May Mimic Fallopian Tube Formation 3Health News:Whole Grain Breakfasts Linked to Lower Heart Failure Risk 2Health News:Blood Tests may Be Possible for Mental Health Conditions 2Health News:DU Test Finds UK Troops Uranium Free 2Health News:Mental Health Conditions Could Be Detected With Blood Tests 2Health News:Children Under Stress Develop More Fevers 2
(Date:11/23/2009)..., WALTHAM,Mass.,Nov.23/PRNewswire/--ProteonThera...dyofitsleadproduct,PRT-201,inend-stagerenaldisease...ft(AVG)creation.TheAVGstudyrepresentsProteon,sseco...slyannouncingtheinitiationofaPhase1/2studyofPRT-20...stula(AVF)creationearlierthisyear.Proteonalsoannou...
(Date:11/23/2009)..., SOUTHSANFRANCISCO,Calif.,Nov.23/PRNewswire-Fir...thatDr.TedW.LoveandDr.DavidC.U,Prichardhaveagreedt...oftheproposedmergerbetweenAnesivaandArcionTherapeu...otescheduledtotakeplaceatthepreviouslyannouncedAne...mber3,2009at9:00a.m.PSTat400OysterPoint,Suite107A,...
(Date:11/23/2009)..., NOVATO,Calif.,Nov.23/PRNewswire-FirstCall/--Ra...sdaq: RPTP ),todayannouncedresultsfromaPhase2bclin...bitartrate("DRCysteamine")inpatientswithnephropath...UniversityofCalifornia,SanDiego("UCSD")GeneralClin...armacokineticsandpharmacodynamicsofasingledoseofDR...
Breaking Medicine Technology:Proteon Initiates Second Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients 2Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 2Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 3Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 2Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 3Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 4Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 5OH2 Medical Spa Achieves the First U S LEED 28R 29 Certification for a Medical Commercial Interior 51691 1OH2 Medical Spa Achieves the First U S LEED 28R 29 Certification for a Medical Commercial Interior 51691 2Leading Blood Centers LifeSource and Central Blood Bank Spotlight a Unique Donor Population During National Hereditary Hemochromatosis Awareness Mon 51690 1Leading Blood Centers LifeSource and Central Blood Bank Spotlight a Unique Donor Population During National Hereditary Hemochromatosis Awareness Mon 51690 2Leading Blood Centers LifeSource and Central Blood Bank Spotlight a Unique Donor Population During National Hereditary Hemochromatosis Awareness Mon 51690 3Leading Blood Centers LifeSource and Central Blood Bank Spotlight a Unique Donor Population During National Hereditary Hemochromatosis Awareness Mon 51690 4Leading Blood Centers LifeSource and Central Blood Bank Spotlight a Unique Donor Population During National Hereditary Hemochromatosis Awareness Mon 51690 5Walking Biking to Work Pays Off 51688 1Walking Biking to Work Pays Off 51688 2
... /PRNewswire/ -- Results from,the primary analysis...study showed that 77 percent of treatment-experien...unavir) 600 mg tablets with,100 mg ritonavir (PREZ...regimen (OBR) of antiretroviral (ARV) agents, reac...48, compared to 68,percent of patients taking Kale...
...al in non-small cell lung cancer -, LOS ANGELES, J...netics, Inc. today announced that positive Phase I...the Journal of Clinical,Oncology suggests that low...-Complementing 1 (ERCC-1) in patient biopsies,with...cts for,sensitivity to cisplatin-based chemotherap...
Other Medicine Technology:New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 2Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 3Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 4
BioPette E Electronic Pipettor, 10-200l
Finnpipette BioControl Single Channel, 40-200ul
...or all liquid handling applications in the laborat...ced operating buttons, and various dispensing tech...tting and diluting make this a lab favorite. It in... pipette without any adverse effects on the variet...
... high performance electronic pipetting! , Soft, ...reduce hand fatigue and strain, Stress-free tip ...ing for easy volume identification, Accepts univ... AdvanTip Low Retention and AdvanTip Precision Pip...
Medicine Products: